Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1 year double-blind RCT in postmenopausal women
Journal of Bone and Mineral Research, Vol. 28 Issue 4, DOI: 10.1002/jbmr.1959
Helen M Macdonald1,‖, h.macdonald at abdn.ac.uk
Adrian D Wood1,‖,
Lorna S Aucott1,
Alison J Black3,
William D Fraser4,
David M Reid1,
Karen R Secombes1,
William G Simpson5,
1 School of Medicine and Dentistry, University of Aberdeen, Foresterhill, Aberdeen
2 School of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen
3 Grampian Osteoporosis Service, Woolmanhill Hospital, Aberdeen
4 Norwich Medical School, University of East Anglia, Norwich, UK
5 Aberdeen Royal Infirmary, Foresterhill, UK
Trial Registration VItamin D effects on CardiOvascular disease Risk (VICtORy) study at controlled-trials.com as ISRCTN20328039 (http://controlled-trials.com/ISRCTN20328039/).
Few year-long vitamin D supplementation trials exist that match seasonal changes. The aim of this study was to determine whether daily oral vitamin D3 at 400 IU or 1000 IU compared with placebo affects annual BMD change in postmenopausal women in a 1-year double blind placebo controlled trial in Scotland. Caucasian women aged 60-70 y (n = 305) were randomized to one of two doses of vitamin D or placebo. All participants started simultaneously in January/February 2009, attending visits at bi-monthly intervals with 265 (87%) women attending the final visit; and an additional visit 1 month after treatment cessation. BMD (Lunar iDXA) and 1,25-dihydroxyvitamin D[1,25(OH)2D], N-terminal propeptide of type 1 collagen [P1NP], C-terminal telopeptide of type I collagen [CTX] and fibroblast growth factor-23 [FGF23] were measured by immunoassay at the start and end of treatment. Circulating PTH, serum Ca and total 25-hydroxyvitamin D [25(OH)D] (latter by tandem mass spectrometry) were measured at each visit.
Mean BMD loss at the hip was significantly less for the
- 1000 IU vitamin D group (0.05 ± 1.46%), compared to the
- 400 IU vitamin D or placebo groups (0.57 ± 1.33% and 0.60 ± 1.67%, respectively) (p < 0.05).
Mean(± SD) baseline 25(OH)D was 33.8 ± 14.6 nmol/L; comparative 25(OH)D change for the placebo, 400 IU and 1000 IU vitamin D groups was: −4.1 ± 11.5 nmol/L, +31. 6 ± 19.8 nmol/L and +42.6 ± 18.9 nmol/L respectively. Treatment did not change markers of bone metabolism, except for small reductions in PTH and serum calcium (latter with 1000 IU dose only). The discordance between the incremental increase in 25(OH)D between the 400IU and 1000 IU vitamin D and effect on BMD suggests that 25(OH)D may not accurately reflect clinical outcome, nor how much vitamin D is being stored.
- Hip fractures reduced 30 percent with 800 IU of vitamin D – meta-analysis July 2012
- 2X to 3X higher hip fracture rate in Asia in past 30 years – Aug 2012
- Guideline following hip fracture – 50000 IU vitamin D daily for 7 days – Jan 2013
- Hip fracture 19 percent less likely with just 4 ng higher level of vitamin D – Dec 2012
- Hip fractures greatly reduced by sunshine, vitamin D, and vitamin K – meta-analysis Sept 2012
- Hip fracture and vitamin D – Health ABC study – May 2012
- 5X increase in hip fracture rates in 65 years - 1998
- 5X fewer hip fractures from Parkinson – Alzheimer – Stroke with enough sun – June 2011
- Overview Fractures and Falls and Vitamin D
- All items in category Falls or Fractures and Vitamin D
- Hip fracture reduced 38 percent with Calcium and just 400 IU of vitamin D – RCT Feb 2013Hip bone loss stopped with 1000 IU of vitamin D, while 400 IU similar to placebo – RCT April 2013
4567 visitors, last modified 16 Mar, 2015,This page is in the following categories (# of items in each category)